First Manhattan’s Revance Therapeutics, Inc. RVNC Stock Holding History

First Manhattan’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7	Closed	-$80	–	1593
2023 Q3	$80	Buy	+7	New	+$135	﹤0.01%	1466

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan's RVNC Position: Q4 2023 in Review

First Manhattan sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 7 shares — an estimated $80 sold.

First Manhattan first reported a position in RVNC in Q3 2023 and held it in 1 quarter. The position peaked at $80 in Q3 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

First Manhattan reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 7 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $80.
First Manhattan first reported a position in Revance Therapeutics, Inc. in Q3 2023 and held it in 1 quarter.
First Manhattan's Revance Therapeutics, Inc. position peaked at $80 in Q3 2023.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.